Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 18/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 4/20 | 0.32 |
| ▸ | UBE2M | P61081 | 1/20 | 0.32 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3091152 | 0.92 | HTR1A (0.37) | CSF1RHTR1AUBE2MDCUN1D1 | |
| SCHEMBL3086415 | 0.86 | CSF1R (0.46) | CSF1RKIT | |
| Trifluoroacetic Acid SCHEMBL3081131 | 0.86 | CSF1R (0.42) | CSF1RHTR1AKIT | |
| SCHEMBL3091147 | 0.85 | CSF1R (0.37) | CSF1RHTR1AKITUBE2MDCUN1D1 | |
| Trifluoroacetic Acid SCHEMBL3081128 | 0.78 | CSF1R (0.41) | CSF1RHTR1AKIT | |
| SCHEMBL3090543 | 0.76 | HTR1A (0.37) | CSF1RHTR1AKIT | |
| Trifluoroacetic Acid SCHEMBL4345533 | 0.76 | CSF1R (0.64) | CSF1RKIT | |
| SCHEMBL13147931 | 0.74 | CSF1R (0.68) | CSF1RKIT | |
| SCHEMBL3078128 | 0.74 | CSF1R (0.34) | CSF1RKIT | |
| SCHEMBL3082388 | 0.74 | CSF1R (0.36) | CSF1RKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | claimed |
| EP-2016057-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-21 | — | — | EP | claimed |
| WO-2007123516-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | WO | claimed |
| US-20060258666-A1 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-16 | — | — | US | claimed |
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| EP-2016057-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007123516-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| US-20060258666-A1 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258666-A1 | c-fms kinase inhibitors | FLT3, FES, FER | CSF1R 111/4885HTR1A 2856/4885KIT 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.